“…The antiatherogenic and anti-inflammatory effects of ARBs have been investigated in previous preclinical (Blessing et al, 2008;Dasu, Riosvelasco, & Jialal, 2009;Fukuda, Enomoto, Hirata, Nagai, & Sata, 2010;Ge et al, 2004;Hadi et al, 2013;Hayashi, Sasamura, Azegami, & Itoh, 2012;Johnstone et al, 2004;Li, Fu, Gao, & Ma, 2010;Shimada et al, 2011;Strawn, Chappell, Dean, Kivlighn, & Ferrario, 2000;Torres et al, 2014;Xu et al, 2007;Xu, Sharma, Li, & Zhao, 2013;Zhao et al, 2014) and clinical studies (Dandona et al, 2003;Gong, Shao, Fu, & Zou, 2015;Graninger, Reiter, Drucker, Minar, & Jilma, 2004;Hirohata et al, 2010;Hirohata et al, 2012;Janic, Lunder, Prezelj, & Šabovic, 2014;Koh et al, 2004;Navalkar, Parthasarathy, Santanam, & Khan, 2001;Rahman et al, 2002;Ramadan et al, 2016;Stumpe et al, 2007;Yamamoto et al, 2011;Yano et al, 2012). Treatment of ApoE-deficient spontaneously hyperlipidemic mice with high-dose candesartan caused a clear regression of atherosclerotic lesions by decreasing lipid-retaining proteoglycan biglycan and suppressing ACAT1 expression (Hayashi et al, 2012).…”